Peptides News and Research

RSS

Efficacy and safety data on linagliptin and investigational compound empagliflozin* in various diabetes subpopulations presented by Boehringer Ingelheim and Eli Lilly and Company

Boehringer Ingelheim and Eli Lilly and Company today announced they will feature five oral and 12 poster presentations for linagliptin and the investigational compound empagliflozin* at the 49th Annual Meeting of the European Association for the Study of Diabetes (EASD) which will take place in Barcelona, from 23 – 27 September. The presentations will add to the already existing body of data on safety and efficacy of these two compounds.

18 Sep 2013

SignaBlok's novel peptide inhibitor of TREM-1 suppresses cancer progression

SignaBlok, Inc., a Massachusetts-based biopharmaceutical company, today announced the successful in vivo proof of concept data that demonstrate that the company's novel mechanism-based, first-in-class peptide inhibitor of TREM-1 effectively suppresses cancer progression in mouse models of lung cancer and dramatically improves survival in septic mice.

18 Sep 2013

Researchers develop synthetic peptide that could be a new class of drugs for heart disease

Researchers at the University of Alberta have developed a synthetic peptide that could be the first in a new class of drugs to treat heart disease, high blood pressure and diabetes.

18 Sep 2013

New method to target, eliminate cancer-supporting macrophages in mouse tumors

When a person has cancer, some of the cells in his or her body have changed and are growing uncontrollably. Most cancer drugs try to treat the disease by killing those fast-growing cells, but another approach called immunotherapy tries to stimulate a person's own immune system to attack the cancer itself.

17 Sep 2013

Researchers identify new link between meal times and daily changes in immune system

A new link between meal times and daily changes in the immune system has been identified by UC San Francisco researchers, and has led them to question assumptions about the roles of specific immune cells in infection and allergy.

17 Sep 2013

Bruker Launches Second Phase Of SISCAPA-MALDI Collaboration

After focusing on confirming the utility and quantitative precision of the SISCAPA-MALDI workflow in the collaboration's first phase, Bruker said it plans to establish fully automated SISCAPA-MALDI capabilities in its demonstration facilities.

16 Sep 2013

ISA Pharmaceuticals announces initiation of ISA101 Phase I/II trial in HIV-positive men with AIN

ISA Pharmaceuticals B.V., a clinical-stage biopharmaceutical company focusing on rationally designed, fully synthetic therapeutic vaccines against cancer and persistent viral infections, today announced the initiation of a Phase I/II clinical study of its lead candidate ISA101 in HIV-positive men suffering from anal intraepithelial neoplasia.

16 Sep 2013

FDA grants orphan drug designation to Soligenix’s SGX94 for treatment of Acute Radiation Syndrome

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that the Office of Orphan Products Development of the US Food and Drug Administration (FDA) has granted orphan drug designation to the active ingredient SGX94 for the treatment of acute radiation syndrome (ARS).

16 Sep 2013

Kinder chemistry promises cleaner and safer pharmaceuticals with fewer side-effects

A new and kinder chemistry promises cleaner and subsequently safer pharmaceuticals with fewer side-effects. The ground-breaking method, developed by a chemistry research group at the University of Copenhagen, is now published in the internationally renowned journal, Chemical Communications, as "Site-selective three component reaction for dual functionalization of peptides".

16 Sep 2013

LifeSensors receives U.S. patent for development of novel DUB substrates

LifeSensors, Inc., a biotech company developing cutting-edge technologies for studying the ubiquitin pathway, has been awarded a U.S. patent for the development of novel, fluorescent di- and poly-ubiquitin deubiquitinase substrates (US 8,518,660).

16 Sep 2013

Circassia: House dust mite allergy treatment meets primary endpoint in phase II clinical study

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced successful results from a phase II clinical study of its house dust mite allergy treatment (House Dust Mite-Synthetic Peptide Immuno-Regulatory Epitope [HDM-SPIRE] based on Circassia’s ToleroMune technology).

12 Sep 2013

Rhythm Awarded $1.35M From Michael J. Fox Foundation

...

10 Sep 2013

Amino acid arginine improves treatment for type 2 diabetes

More than 371 million people worldwide suffer from diabetes, of whom 90% are affected by lifestyle-related diabetes mellitus type 2 (type 2 diabetes).

10 Sep 2013

Basic fibroblast growth factor can protect endplate in motor neurons of injured spinal cord

In current studies, the degeneration and protection measures in the distal end of the injured spinal cord and target organ muscle effector have scarcely been investigated. The distal end of the spinal cord and neuromuscular junction may develop secondary degenera-tion and damage following spinal cord injury because of the loss of neural connections.

7 Sep 2013

Thrombogenics, Bicycle Collaborate On Drugs Targeting Eye Diseases

...

5 Sep 2013

ThromboGenics, Bicycle to develop and commercialize novel drugs for ophthalmic diseases

ThromboGenics NV, a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that it has entered into a collaboration and license agreement with Bicycle Therapeutics to develop and commercialize novel drugs inhibiting a specific target for the treatment of ophthalmic diseases, such as diabetic macular edema.

5 Sep 2013

65 metabolites in urine simultaneously measured by clinical IEM-by-NMR screening study in Turkey

At the 12th International Congress of Inborn Errors of Metabolism (www.iciem2013.com), Bruker announces another milestone in the cost-effective use of NMR (nuclear magnetic resonance) spectroscopy screening as a clinical research tool for metabolic screening and small molecule in vitro diagnostics (IVD) research and validation.

4 Sep 2013

Results from Phase II START study published in The Lancet Diabetes & Endocrinology

Results from the START clinical study (Study of Thymoglobulin to Arrest Newly Diagnosed Type 1 Diabetes), led by Dr. Steve Gitelman (University of California, San Francisco) and sponsored by the Immune Tolerance Network, are published today in The Lancet Diabetes & Endocrinology.

28 Aug 2013

Study reveals role of cadherin receptor BT-R3 in killing action of Cry4B mosquito toxin

Researchers at The University of Texas at Dallas (UTD), led by Dr. Lee Bulla, have demonstrated for the first time the selective cytotoxicity of Bacillus thuringiensis subsp. israelensis Cry4B toxin is mediated by BT-R3.

27 Aug 2013

Ultimate DIY book for laboratory chemists in search of next generation medicines

Pharmaceuticals of the future will be fashioned using the human body's own chemical substances, proteins and peptides. And now, University of Copenhagen chemists have published the ultimate DIY book for laboratory chemists in search of this next generation of medicines.

23 Aug 2013

Peptides News and Research

Efficacy and safety data on linagliptin and investigational compound empagliflozin* in various diabetes subpopulations presented by Boehringer Ingelheim and Eli Lilly and Company

SignaBlok's novel peptide inhibitor of TREM-1 suppresses cancer progression

Researchers develop synthetic peptide that could be a new class of drugs for heart disease

New method to target, eliminate cancer-supporting macrophages in mouse tumors

Researchers identify new link between meal times and daily changes in immune system

Bruker Launches Second Phase Of SISCAPA-MALDI Collaboration

ISA Pharmaceuticals announces initiation of ISA101 Phase I/II trial in HIV-positive men with AIN

FDA grants orphan drug designation to Soligenix’s SGX94 for treatment of Acute Radiation Syndrome

Kinder chemistry promises cleaner and safer pharmaceuticals with fewer side-effects

LifeSensors receives U.S. patent for development of novel DUB substrates

Circassia: House dust mite allergy treatment meets primary endpoint in phase II clinical study

Rhythm Awarded $1.35M From Michael J. Fox Foundation

Amino acid arginine improves treatment for type 2 diabetes

Basic fibroblast growth factor can protect endplate in motor neurons of injured spinal cord

Thrombogenics, Bicycle Collaborate On Drugs Targeting Eye Diseases

ThromboGenics, Bicycle to develop and commercialize novel drugs for ophthalmic diseases

65 metabolites in urine simultaneously measured by clinical IEM-by-NMR screening study in Turkey

Results from Phase II START study published in The Lancet Diabetes & Endocrinology

Study reveals role of cadherin receptor BT-R3 in killing action of Cry4B mosquito toxin

Ultimate DIY book for laboratory chemists in search of next generation medicines

Editorial Focus eBook - Peptides and Oligonucleotides (2nd edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News